Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.77 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.77 |
| ▸ | CYP4Z1 | Q86W10 | 3/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | CYP4F11 | Q9HBI6 | 1/20 | 0.49 |
| ▸ | CYP4F12 | Q9HCS2 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.46 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23512483 | 0.95 | CYP4F2 (0.70) | CYP4F2CYP4A11CYP4Z1TDP1HRH3 | |
| SCHEMBL68902 | 0.94 | CYP4F2 (0.85) | CYP4F2CYP4A11CYP4Z1TDP1HRH3 | |
| SCHEMBL765847 | 0.89 | CYP4F2 (0.62) | CYP4F2CYP4A11CYP4Z1TDP1CYP4F11 | |
| SCHEMBL363982 | 0.89 | CYP4F2 (0.77) | CYP4F2CYP4A11CYP4Z1TDP1HRH3 | |
| SCHEMBL10206072 | 0.89 | CYP4F2 (0.77) | CYP4F2CYP4A11CYP4Z1TDP1HRH3 | |
| SCHEMBL11437256 | 0.89 | CYP4F2 (0.77) | CYP4F2CYP4A11CYP4Z1TDP1HRH3 | |
| SCHEMBL21171688 | 0.87 | CYP4F2 (0.60) | CYP4F2CYP4A11CYP4Z1HRH3LMNA | |
| SCHEMBL7766764 | 0.87 | CYP4F2 (0.70) | CYP4F2CYP4A11CYP4Z1TDP1EPHX2 | |
| SCHEMBL22098222 | 0.87 | CYP4F2 (1.00) | CYP4F2CYP4A11CYP4Z1TDP1HRH3 | |
| SCHEMBL1587300 | 0.87 | CYP4F2 (0.74) | CYP4F2CYP4A11CYP4Z1TDP1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106414434-B | Isothiazole derivatives as GPR120 agonists for the treatment of type II diabetes | 詹森药业有限公司 | 2019-12-31 | — | — | CN | disclosed |
| US-20170158521-A1 | EMM-28, A NOVEL SYNTHETIC CRYSTALLINE MATERIAL, ITS PREPARATION AND USE | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY | 2017-06-08 | — | — | US | disclosed |
| US-9102599-B2 | N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-08-11 | — | — | US | disclosed |
| US-20130184279-A1 | N-((3-BENZYL)-2,2-(BIS-PHENYL)-PROPAN-1-AMINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-18 | — | — | US | disclosed |
| US-8404896-B2 | N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-26 | — | — | US | disclosed |
| US-20120322761-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-12-20 | — | — | US | disclosed |
| US-8304403-B2 | Heterocyclic CETP inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-06 | — | — | US | disclosed |
| EP-1951673-B1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-09-05 | — | — | EP | disclosed |
| EP-1951690-B1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-03-28 | — | — | EP | disclosed |
| EP-2094643-B1 | N-((3-BENZYL)-2,2-(BIS-PHENYL)-PROPAN-1-AMINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASES | BRISTOL MYERS SQUIBB CO (US) | 2012-02-29 | — | — | EP | disclosed |
| US-7652023-B2 | Heterocyclic CETP inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-01-26 | — | — | US | disclosed |
| WO-2008070496-A2 | N- ( (3-BENZYL) -2, 2- (BIS-PHENYL) -PROPAN-1-AMINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-12 | — | — | WO | disclosed |
| US-20080027094-A1 | Tropane Compounds and Pharmaceutical Compositions Comprising the Same as an Active Ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-01-31 | — | — | US | disclosed |
| US-20080027094-A1 | Tropane Compounds and Pharmaceutical Compositions Comprising the Same as an Active Ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-01-31 | — | — | US | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| US-20070135467-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| WO-2007062314-A2 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007062308-A2 | HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
| EP-1785421-A1 | TROPAN COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | CYP4F2 1512/4885CYP4A11 357/4885CYP4Z1 1859/4885 |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | CYP4F2 1512/4885CYP4A11 357/4885CYP4Z1 1859/4885 |
| US-20080027094-A1 | Tropane Compounds and Pharmaceutical Compositions Comprising the Same as an Active Ingredient | CHRM1, CHRM3, CHRM2 | CYP4F2 2082/4885CYP4A11 827/4885CYP4Z1 1755/4885 |
| US-20070135467-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | CYP4F2 1512/4885CYP4A11 357/4885CYP4Z1 1859/4885 |
| US-20120322761-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | CYP4F2 1512/4885CYP4A11 357/4885CYP4Z1 1859/4885 |
| US-20170158521-A1 | EMM-28, A NOVEL SYNTHETIC CRYSTALLINE MATERIAL, ITS PREPARATION AND USE | CD14, ERG28, DAP3 | CYP4F2 2148/4885CYP4A11 3171/4885CYP4Z1 2079/4885 |
| US-20130184279-A1 | N-((3-BENZYL)-2,2-(BIS-PHENYL)-PROPAN-1-AMINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASES | CETP, APOB, CES1 | CYP4F2 2388/4885CYP4A11 463/4885CYP4Z1 2229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.